CCS1477, a CBP inhibitor, is being explored to treat NHL, MM, AML, and MDS in a phase I/IIa trial (NCT04068597).712 Agents targeting readers include BET inhibitors. The gene discussed is DNER; the disease is Miyoshi myopathy.